Neurocrine Biosciences Inc. (NBIX) shared new results from a one-year clinical study at the Endocrine Society's 2025 Annual Meeting in San Francisco. The study looked at both adults and children with classic congenital adrenal hyperplasia who were treated with CRENESSITY (crinecerfont). Patients saw clear reductions in weight and also showed major improvements in insulin resistance compared to those who received a placebo.
The promising results came from Phase 3 CAHtalyst trials and suggest that CRENESSITY could help improve long-term health outcomes for people with those condition.
"These data presented at ENDO, which include both pediatric and adult patients, showed that the reduction in steroid doses enabled by CRENESSITY can lead to meaningful improvements in cardiometabolic outcomes. The use of CRENESSITY with glucocorticoid treatment is evolving the standard of care for classic congenital adrenal hyperplasia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.